Raymond James Initiates Coverage On Aktis Oncology with Strong Buy Rating, Announces Price Target of $40
Benzinga Newsdesk 4 months ago
NewsPrice TargetInitiationAnalyst Ratings
Raymond James analyst Christopher Raymond initiates coverage on Aktis Oncology (NASDAQ:AKTS) with a Strong Buy rating and announces Price Target of $40.
Raymond James analyst Christopher Raymond initiates coverage on Aktis Oncology (NASDAQ:AKTS) with a Strong Buy rating and announces Price Target of $40.